About this item:

896 Views | 770 Downloads

Author Notes:

Email Address: David S. Yu :david.sungwen.yu@emory.edu Jerome Landry:jland01@emory.edu

J Cheng contributed to collection of data, establishing the database, analysis and interpretation of data, and drafting of the manuscript.

MH Squires III contributed to collection of data, establishing the database, and analysis and interpretation of data.

SB Fisher, SK Maithel contributed to collection of data, establishing the database, interpretation of data, and critical evaluation of manuscript.

JL Mikell, WJ Curran Jr contributed to interpretation of data and critical evaluation of manuscript.

WA Hall, LE Colbert, JW Shelton contributed to study design, interpretation of data, and critical evaluation of manuscript.

CA Staley III, DA Kooby, BF El-Rayes contributed to acquisition of data and critical evaluation of manuscript.

JLandry, DS Yu contributed to study design, analysis and interpretation of data, and drafting of manuscript. All authors read and approved the final manuscript.

Disclosure: The authors declare no conflict of interest.

Subjects:

Research Funding:

This work was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Numbers ULl TR000454 to LEC and SBF and TLlTR000456 to LEC.

Keywords:

  • D2 lymphadenectomy
  • Gastric adenocarcinoma (GAC)
  • Intergroup 0116 trial (INT-0116 trial)
  • Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial (MAGIC trial)
  • patterns of care
  • radiation therapy

Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience.

Show all authors Show less authors

Tools:

Journal Title:

Journal of Gastrointestinal Oncology

Volume:

Volume 6, Number 3

Publisher:

, Pages 247-253

Type of Work:

Article | Final Publisher PDF

Abstract:

Gastric adenocarcinoma (GAC) is one of the most commonly diagnosed cancers worldwide. Two standard approaches for treatment of resectable GAC include adjuvant 5-fluorouracil-based chemoradiotherapy [per Intergroup 0116 (INT-0116) trial and perioperative epirubicin, cisplatin, fluorouracil (ECF) chemotherapy per Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial]. Controversy remains regarding the most appropriate treatment strategy to decrease recurrence rates and improve survival following surgery. The purpose of this study was to analyze how patterns of care for patients with GAC treated at Emory University Hospital changed following publication of the MAGIC trial in 2006.

Copyright information:

©2015 Journal of Gastrointestinal Oncology

Export to EndNote